Table 1.
For major sub-groups, numbers of deaths by defined opioid-specificity and person-years (pys) at risk since first CHI-identified prescription to earlier of death-date or 31 December 2013.
| Sub-group defined by 1st CHI-identified prescription | Clients | Non-DRDs | DRDs |
Opioid-specific DRD sub-groups |
Person-years, pys | ||
|---|---|---|---|---|---|---|---|
| Heroin: yes | Heroin: no | Heroin: yes | |||||
| Meth: no | Meth: yes | Meth: yes | |||||
| Bupren: no | Bupren: no | Bupren: no | |||||
| Scotland-wide | 33 128 | 1171 | 760 | 173 | 362 | 151 | 121 254 pys |
| Death-rate per | 9.7 | 6.3 | 1.4 | 3.0 | 1.2 | ||
| 1000 pys (95% CI) | (9.1–10.2) | (5.8–6.7) | (1.2–1.6) | (2.7–3.3) | (1.0–1.4) | ||
| Prescription source | |||||||
| GP-prescription | 22 114 | 887 | 502 | 130 | 232 | 86 | 84 338 pys |
| Death-rate per | 10.5 | 6.0 | 1.5 | 2.8 | 1.0 | ||
| 1000 pys (95% CI) | (9.8–11.2) | (5.4–6.5) | (1.3–1.8) | (2.4–3.1) | (0.8–1.2) | ||
| Other-source | 11 014 | 284 | 258 | 43 | 130 | 65 | 36 916 pys |
| Death-rate per | 7.7 | 7.0 | 1.2 | 3.5 | 1.8 | ||
| 1000 pys (95% CI) | (6.8–8.6) | (6.1–7.8) | (0.8–1.5) | (2.9–4.1) | (1.3–2.2) | ||
| Gender | |||||||
| Males | 22 025 | 827 | 535 | 141 | 240 | 108 | 80 394 pys |
| Death-rate per | 10.3 | 6.7 | 1.8 | 3.0 | 1.3 | ||
| 1000 pys (95% CI) | (9.6–11.0) | (6.1–7.2) | (1.4–2.0) | (2.6–3.4) | (1.1–1.6) | ||
| Females | 11 103 | 344 | 225 | 32 | 122 | 43 | 40 860 pys |
| Death-rate per | 8.4 | 5.5 | 0.8 | 3.0 | 1.1 | ||
| 1000 pys (95% CI) | (7.5–9.3) | (4.8–6.2) | (0.5–1.1) | (2.4–3.5) | (2.4–3.5) | ||
| Age-group at Cohort-Entry | |||||||
| 35+ years @ Cohort-entry | 16 002 | 886 | 451 | 78 | 244 | 86 | 58 462 pys |
| Death-rate per | 15.2 | 7.7 | 1.3 | 4.2 | 1.5 | ||
| 1000 pys (95% CI) | (14.2–16.2) | (7.0–8.4) | (1.0–1.6) | (3.6–4.7) | (1.2–1.8) | ||
| < 35 years @ Cohort-entry |
17 126 | 285 | 309 | 95 | 118 | 65 | 62 792 pys |
| Death-rate per | 4.5 | 4.9 | 1.5 | 1.9 | 1.0 | ||
| 1000 pys (95% CI) | (4.0–5.1) | (4.4–5.5) | (1.2–1.8) | (1.5–2.2) | (0.8–1.3) | ||
| Gender by Age-group at Cohort-Entry: interaction | |||||||
| Male, 35+ | 11 540 | 632 | 320 | 68 | 163 | 63 | 42 126 pys |
| Death-rate per | 15.0 | 7.6 | 1.6 | 3.9 | 1.5 | ||
| 1000 pys (95% CI) | (13.8–16.2) | (6.8–8.4) | (1.2–2.0) | (3.3–4.5) | (1.1–1.9) | ||
| Female, 35+ | 4 462 | 254 | 131 | 10 | 81 | 23 | 16 336 pys |
| Death-rate per | 15.5 | 8.0 | 0.6 | 5.0 | 1.4 | ||
| 1000 pys (95% CI) | (13.6–17.5) | (6.6–9.4) | (0.3–1.1) | (3.9–6.0) | (0.9–2.1) | ||
| Male, < 35 | 10 485 | 195 | 215 | 73 | 77 | 45 | 38 268 pys |
| Death-rate per | 5.1 | 5.6 | 1.9 | 2.0 | 1.0 | ||
| 1000 pys (95% CI) | (4.4–5.8) | (4.8–6.4) | (1.5–2.4) | (1.5–2.5) | (0.8–1.5) | ||
| Female, < 35 | 6 641 | 90 | 94 | 22 | 41 | 20 | 24 524 pys |
| Death-rate per | 3.7 | 3.8 | 0.9 | 1.7 | 0.8 | ||
| 1000 pys (95% CI) | (2.9–4.4) | (3.1–4.6) | (0.5–1.4) | (1.1–2.2) | (0.5–1.3) | ||
| Region at cohort entry | |||||||
| G. Glasgow & Clyde | 12 261 | 525 | 307 | 82 | 135 | 56 | 47 465 pys |
| Death-rate per | 11.1 | 6.5 | 1.7 | 2.8 | 1.2 | ||
| 1000 pys (95% CI) | (10.2–12.0) | (5.8–7.2) | (1.4–2.1) | (2.6–4.3) | (0.9–1.5) | ||
| Lothian | 4 801 | 170 | 84 | 10 | 58 | 11 | 17 423 pys |
| Death-rate per | 9.8 | 4.8 | 0.6 | 3.3 | 0.6 | ||
| 1000 pys (95% CI) | (8.4–11.3) | (3.9–6.0) | (0.3–1.1) | (2.5–4.2) | (0.4–1.1) | ||
| Tayside | 2 760 | 87 | 74 | 7 | 34 | 23 | 8 034 pys |
| Death-rate per | 10.8 | 9.2 | 0.9 | 4.2 | 2.9 | ||
| 1000 pys (95% CI) | (8.8–13.4) | (7.3–11.6) | (0.4–1.8) | (3.0–5.9) | (1.9–4.3) | ||
| Rest of Scotland | 13 306 | 389 | 295 | 74 | 135 | 61 | 48 335 pys |
| Death-rate per | 8.0 | 6.1 | 1.5 | 2.8 | 1.3 | ||
| 1000 pys (95% CI) | (7.2–8.8) | (5.4–6.8) | (1.2–1.9) | (2.4–3.3) | (1.0–1.6) | ||